TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name GW841819X
Drug Type Small molecule
TTD ID D03LIP
Toxicity Organism Test Type Route(Dose)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Decreasing Drug Toxicity
Hide/Show
Combination Pair ID: 536
Pair Name Vitamin C, GW841819X
Partner Name Vitamin C
Disease Info [ICD-11: 2C30] Melanoma Investigative
Gene Regulation Down-regulation Expression BRD4 hsa23476
Down-regulation Expression H4C12 hsa8362
Down-regulation Expression HAT1 hsa8520
Down-regulation Expression HRH4 hsa59340
In Vitro Model A2058 Amelanotic melanoma Homo sapiens (Human) CVCL_1059
SK-MEL-28 Cutaneous melanoma Homo sapiens (Human) CVCL_0526
SK-MEL-2 Melanoma Homo sapiens (Human) CVCL_0069
C8161 Cutaneous melanoma Homo sapiens (Human) CVCL_6813
1205Lu Cutaneous melanoma Homo sapiens (Human) CVCL_5239
In Vivo Model Mice were then engrafted on the neck by injecting 2×10⁵ mouse melanoma cells, B16-F10, to produce experimental tumor.
Result This study shows that ascorbate can enhance the efficacy of BET inhibitors, providing a possible clinical solution to challenges arising in phase I trials from the dose-dependent side effects of this class of epigenetic therapy.
03. Reference
No. Title Href
1 Vitamin C Sensitizes Melanoma to BET Inhibitors. Cancer Res. 2018 Jan 15;78(2):572-583. doi: 10.1158/0008-5472.CAN-17-2040. Click
It has been 58837 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP